Results 181 to 190 of about 33,791,512 (292)

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Glucagon-like peptide-1-based therapies and the intersection of metabolic and skin disease. [PDF]

JAAD Case Rep
Ormaza-Vera A, Enos CW.
europepmc   +1 more source

How the Sea Salt Chocolate Cookie Became a Thing: The Role of Flavor Pairing in Obesity

Obesity, EarlyView.
Proposed framework illustrating how flavor pairing and multisensory flavor architecture may sustain hedonic eating through enhanced palatability, reward preservation, delayed sensory‐specific satiety, and post‐ingestive signaling, thereby promoting excess energy intake and obesity risk.
Mohammed Ayyad, Eugene Kim
wiley   +1 more source

Use of glucagon-like peptide-1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes. [PDF]

J Diabetes Investig
Ogawa O.
europepmc   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source

Incretin‐Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency

Obesity, EarlyView.
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee, Caroline M. Apovian, Nawfal Istfan   +2 more
wiley   +1 more source

Weight Self‐Stigma and Food Noise During Post‐Metabolic Bariatric Surgery Weight Stability

Obesity, EarlyView.
ABSTRACT Objective Food noise has been studied with GLP‐1‐based therapies, but not with metabolic bariatric surgery (MBS), despite shared mechanisms. Data on food noise beyond initial weight loss are limited, and weight self‐stigma (WSS), which links to poorer weight outcomes and risky behaviors after MBS, may relate to higher food noise, especially ...
Dale S. Bond, Yin Wu, Pavlos K. Papasavas, Michael E. Levin, Rebecca M. Puhl, Dahlia Saad‐Pendergrass, Devika Umashanker, Darren Tishler, Jason Lillis   +8 more
wiley   +1 more source

Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity. [PDF]

J Neurol Sci
Chen H, Lakhani DA, Yaddanapudi SS, Latifikhereshky S, Rai P, Kakadiya J, Malhotra A, Colasurdo M, Gandhi D.   +8 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure

Otolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo, Sammy Y. Gao, Shaun A. Nguyen, Mohamed Abdelwahab   +3 more
wiley   +1 more source

Glucagon-like-peptide-1 receptor agonists in the intensive care unit: practical implications for the intensivists. [PDF]

Crit Care Sci
Bianchini L, Martins GAR, Myatra SN.
europepmc   +1 more source